left-arrow right-arrow pinterest facebook google_plus linkedin

HCRN GI14-198


Recruiting | Phase II

Official Title:

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients.

Study Purpose:

To find out the effects, good and/or bad, of adding the study agent ramucirumab to the usual chemotherapy regimen.


  • Arm A will receive the usual treatment mFOLFIRINOX plus the study agent ramucirumab.
  • Arm B:will receive the usual treatment mFOLFIRINOX plus a placebo.

Key Participation Requirements:


Female or Male


19 years and older


Advanced pancreatic adenocarcinoma cancer that has spread to other parts of your body


No prior treatment for metastatic or recurrent disease.

Chemotherapy and/or radiation given before or after surgery with disease that has grown after 6 months is allowed.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

HCRN GI14-198

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!